An interesting LinkedIn post in the aftermath of EHA. Including statements from JJ and Kontro.
MaryLynn Schiavi
Communications Business Partner, Clinical Sciences & Operations, R&D, Sanofi
“In a recent interview, the CEO of Faron stated that Bexmarilimab could have application across a range of cancers.”
MaryLynn Schiavi is a high-level communications director and strategist (Communications Business Partner) for the global pharma giant Sanofi (10+ billion in cash). She works at Sanofi specifically at the core of clinical sciences, operations, and research and development (R&D).
No need to rush to the market square just yet, but worth keeping an eye on…